MX2016016404A - Metodos para el tratamiento del prurito. - Google Patents

Metodos para el tratamiento del prurito.

Info

Publication number
MX2016016404A
MX2016016404A MX2016016404A MX2016016404A MX2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A MX 2016016404 A MX2016016404 A MX 2016016404A
Authority
MX
Mexico
Prior art keywords
methods
pruritus
present
treating
treating pruritus
Prior art date
Application number
MX2016016404A
Other languages
English (en)
Inventor
Sciascia Thomas
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2016016404A publication Critical patent/MX2016016404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del prurito con composiciones antipruriginosas; la presente invención, entre otros, proporciona métodos para el tratamiento de varias afecciones pruriginosas mediante el uso de nalbufina o un éster o sal farmacéuticamente aceptable de ésta; en una modalidad, la presente invención proporciona métodos para el tratamiento de prurito que comprende administrar una cantidad eficaz de un agente antipruriginoso a un sujeto que precise dicho tratamiento, en donde el agente antipruriginoso es nalbufina o un éster o sal farmaceúticamente aceptable de ésta.
MX2016016404A 2014-06-13 2015-06-12 Metodos para el tratamiento del prurito. MX2016016404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462011936P 2014-06-13 2014-06-13
PCT/US2015/035650 WO2015192071A1 (en) 2014-06-13 2015-06-12 Methods for treating pruritus

Publications (1)

Publication Number Publication Date
MX2016016404A true MX2016016404A (es) 2017-11-30

Family

ID=54834447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016404A MX2016016404A (es) 2014-06-13 2015-06-12 Metodos para el tratamiento del prurito.

Country Status (12)

Country Link
US (2) US20150359789A1 (es)
EP (1) EP3154546A4 (es)
JP (1) JP2017517553A (es)
KR (1) KR20170016983A (es)
CN (1) CN106535897A (es)
AU (1) AU2015274327A1 (es)
BR (1) BR112016029236A2 (es)
CA (1) CA2951420A1 (es)
IL (1) IL249475A0 (es)
MX (1) MX2016016404A (es)
RU (1) RU2017101102A (es)
WO (1) WO2015192071A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US20170216277A1 (en) * 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN109310656A (zh) * 2016-03-21 2019-02-05 特雷维治疗股份有限公司 尿毒症性瘙痒症的治疗
KR20190073385A (ko) * 2016-10-25 2019-06-26 트레비 테라퓨틱스, 인코포레이티드 결정성 양진의 치료법
EP3755328A4 (en) * 2018-03-29 2021-11-10 Lumosa Therapeutics Co., Ltd. COMPOSITIONS AND METHODS OF TREATMENT OF PRURITUS
WO2020014342A1 (en) * 2018-07-11 2020-01-16 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
US20200022974A1 (en) * 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
WO2021142288A1 (en) * 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402005B1 (en) * 2005-08-24 2020-12-16 Endo Pharmaceuticals Inc. Sustained release formulations of nalbuphine
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2008128892A1 (en) * 2007-04-23 2008-10-30 Symrise Gmbh & Co. Kg Polyethylene glycol esters and cosmetic and/or dermatological preparations
US20140179727A1 (en) * 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) * 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
MX2015007518A (es) * 2012-12-14 2016-03-01 Trevi Therapeutics Inc Metodos para tratar el prurito.

Also Published As

Publication number Publication date
CN106535897A (zh) 2017-03-22
US20190099416A1 (en) 2019-04-04
RU2017101102A (ru) 2018-07-16
EP3154546A1 (en) 2017-04-19
EP3154546A4 (en) 2018-01-10
BR112016029236A2 (pt) 2017-11-07
IL249475A0 (en) 2017-02-28
AU2015274327A1 (en) 2017-01-05
WO2015192071A1 (en) 2015-12-17
JP2017517553A (ja) 2017-06-29
US20150359789A1 (en) 2015-12-17
KR20170016983A (ko) 2017-02-14
CA2951420A1 (en) 2015-12-17
RU2017101102A3 (es) 2019-01-28

Similar Documents

Publication Publication Date Title
MX2016016404A (es) Metodos para el tratamiento del prurito.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12015502075B1 (en) Treatment of cataplexy
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2017000980A (es) Composiciones de tratamiento.
MX2017000976A (es) Composiciones de tratamiento.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2015012741A (es) Palbociclib deuterado.
NZ708371A (en) Methods for treating pruritus
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MA39824A (fr) Composés azole amido-substitués
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2018011379A (es) Tratamiento del prurito uremico.
MX2018001684A (es) Metodo de curacion de heridas.